^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Viral replication inhibitor

    Related drugs:
    3d
    ZELA: Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) (clinicaltrials.gov)
    P2/3, N=366, Recruiting, Airway Therapeutics, Inc. | Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2027 --> Mar 2028
    Enrollment open • Trial primary completion date
    3d
    TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2 (clinicaltrials.gov)
    P=N/A, N=1178, Completed, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Recruiting --> Completed | Trial completion date: Jun 2024 --> Sep 2025 | Trial primary completion date: Jun 2024 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    7d
    Study Investigating the Safety and Immunogenicity of AB-729 and VTP 300 in Virologically Suppressed CHB Participants (ACTRN12622000317796)
    P2, N=62, Completed, Arbutus Biopharma | Active, not recruiting --> Completed
    Trial completion
    |
    Opdivo (nivolumab)
    10d
    A Study of RBD1016 in CHB Participants (clinicaltrials.gov)
    P2, N=48, Completed, Suzhou Ribo Life Science Co. Ltd. | Active, not recruiting --> Completed
    Trial completion
    16d
    PRIOH-1: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (clinicaltrials.gov)
    P3, N=158, Completed, AiCuris Anti-infective Cures AG | Active, not recruiting --> Completed
    Trial completion
    |
    Zyclara (imiquimod)
    16d
    A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions. (clinicaltrials.gov)
    P=N/A, N=99000, Active, not recruiting, Pfizer
    New trial • Real-world evidence
    23d
    A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19. (clinicaltrials.gov)
    P=N/A, N=8252912, Completed, Pfizer | Recruiting --> Completed | Trial completion date: Dec 2025 --> Feb 2025 | Trial primary completion date: Dec 2025 --> Feb 2025
    Trial completion • Trial completion date • Trial primary completion date • HEOR • Real-world evidence
    27d
    A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects (clinicaltrials.gov)
    P1, N=165, Completed, Aligos Therapeutics | Active, not recruiting --> Completed
    Trial completion • First-in-human
    28d
    Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 (clinicaltrials.gov)
    P2, N=67, Completed, GemVax & Kael | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Sep 2025
    Trial completion • Trial completion date
    |
    LucaVax (tertomotide)
    28d
    PanoramicNOR: PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway (clinicaltrials.gov)
    P3, N=2000, Active, not recruiting, Haukeland University Hospital | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Jun 2027 | Trial primary completion date: Apr 2024 --> Sep 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    28d
    A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension (clinicaltrials.gov)
    P1, N=18, Completed, Vigonvita Life Sciences | Not yet recruiting --> Completed
    Trial completion
    30d
    Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects (clinicaltrials.gov)
    P1, N=59, Completed, GemVax & Kael | Recruiting --> Completed | Trial completion date: Dec 2025 --> Aug 2025
    Trial completion • Trial completion date
    |
    LucaVax (tertomotide)